Charisela develops breakthrough adiponectin assay

Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it has developed an adiponectin assay with major advantages over existing technologies, including the elimination of dilutions. Adiponectin (Acrp30), an adipocytokine, is important in many therapeutic arenas, including type 2 diabetes, obesity, atherosclerosis, and rheumatoid arthritis.

“Adiponectin concentration at normal serum levels is in the μg/mL range”

"Adiponectin concentration at normal serum levels is in the μg/mL range," said Robert Danielzadeh, Charisela's founder. "Other products require high dilutions, several hours to run and many wash steps. This added complexity takes time and often compromises the results," he stated.

The new assay's advantages represent major breakthroughs in the testing of adiponectin. While ELISA tests typically require dilutions of 1,000 to 1, the Charisela assay can directly quantitate adiponectin at normal levels naturally occurring in serum. This saves time, increases accuracy, and decreases costs.

Charisela's assay is ready for analysis in about one hour and requires only one wash step. Danielzadeh explained that the Company is focused on optimizing each step of the assay process: preparation of the samples that doesn't require time consuming and error inducing dilution steps; and a simple procedure that requires minimal steps and can be done in about an hour.

Charisela's patent pending platform technology enables rapid assay development and the Company will be announcing several new products over the next several months.